USS Investment Management Ltd Sells 10,154 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• USS Investment Management Ltd has decreased its stake in Thermo Fisher Scientific by 13.8%, selling 10,154 shares and retaining 63,252 shares valued at approximately $31.48 million.
• Thermo Fisher Scientific recently reported quarterly earnings of $5.36 per share, exceeding estimates, with revenue of $10.86 billion, a 2.9% year-over-year increase.
• The company is set to distribute a quarterly dividend of $0.43 per share on October 15th, with a yield of 0.3%.

USS Investment Management Ltd lowered its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 13.8% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 63,252 shares of the medical research company's stock after selling 10,154 shares during the period. USS Investment Management Ltd's holdings in Thermo Fisher Scientific were worth $31,480,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in TMO. Bernard Wealth Management Corp. acquired a new position in Thermo Fisher Scientific during the fourth quarter worth $25,000. Ameriflex Group Inc. acquired a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth about $30,000. Keystone Global Partners LLC bought a new stake in Thermo Fisher Scientific during the first quarter valued at about $31,000. IMA Advisory Services Inc. acquired a new stake in shares of Thermo Fisher Scientific in the first quarter valued at about $35,000. Finally, Smallwood Wealth Investment Management LLC acquired a new stake in shares of Thermo Fisher Scientific in the first quarter valued at about $37,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO traded down $5.38 during midday trading on Wednesday, reaching $477.03. 1,442,085 shares of the company traded hands, compared to its average volume of 2,409,042. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $623.77. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The stock's 50-day simple moving average is $463.59 and its 200-day simple moving average is $452.20. The firm has a market cap of $180.13 billion, a PE ratio of 27.59, a PEG ratio of 2.60 and a beta of 0.75.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. During the same quarter in the previous year, the company earned $5.37 EPS. The firm's revenue for the quarter was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's payout ratio is currently 9.95%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. Scotiabank raised Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price target on the stock in a research report on Friday, July 11th. Evercore ISI cut their target price on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a research note on Tuesday, July 8th. Hsbc Global Res downgraded shares of Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 24th. Raymond James Financial reiterated an "outperform" rating and issued a $535.00 target price (up previously from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Finally, William Blair started coverage on Thermo Fisher Scientific in a report on Monday, August 18th. They issued an "outperform" rating for the company. Sixteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $589.38.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the transaction, the executive vice president directly owned 22,367 shares in the company, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Joseph R. Holmes sold 385 shares of the company's stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the transaction, the chief accounting officer owned 2,319 shares in the company, valued at approximately $1,142,408.97. The trade was a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 30,066 shares of company stock valued at $14,182,963 over the last ninety days. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.